Related Experiment Video
Updated: Jul 14, 2026

08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
15.9K
Transcriptomic Landscape Analysis Reveals a Persistent DNA Damage Response in Metabolic Dysfunction-associated
Zi-Yuan Zou1,2, Tian-Yi Ren1, Jia-Qi Li2,3
1Center for Fatty Liver, Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Journal of Clinical and Translational Hepatology
|September 16, 2024
Summary
Metabolic dysfunction-associated steatotic liver disease (MASLD) remission may not fully resolve liver damage signals. Persistent DNA damage response and P53 activation after diet reversal indicate potential for MASLD recurrence.
Area of Science:
- Hepatology
- Molecular Biology
- Genomics
Background:
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent global liver condition.
- Lifestyle modification is the primary management strategy for MASLD.
- Persistent molecular signals in MASLD post-remission remain poorly understood.
Purpose of the Study:
- To investigate persistent transcriptomic changes in the liver following MASLD reversal.
- To identify molecular mechanisms contributing to potential MASLD relapse.
Main Methods:
- Mice were fed a Western diet (WD) or chow diet (CD), or underwent diet reversal from WD to CD.
- Liver RNA sequencing was performed to analyze transcriptomic profiles.
- Data from P53-knockout mice and human MASLD samples were integrated.
Main Results:
- Dietary reversal of WD-induced MASLD revealed persistent activation of the DNA damage response (DDR) and P53.
- Elevated P53 correlated with hepatocyte ballooning, suggesting a role in apoptosis.
- P53 knockout reduced apoptosis signaling; P53 may upregulate apoptosis-enhancing nuclease (AEN).
Conclusions:
- The P53-AEN-apoptosis axis and DDR signaling are upregulated during and after WD exposure in the liver.
- These findings offer insights into MASLD relapse mechanisms.
- DDR signaling presents a potential therapeutic target for preventing MASLD recurrence.

